Posted by Michael Wonder on 03 May 2022
Belite Bio receives FDA fast track designation for LBS-008
3 May 2022 - LBS-008 (aka tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease.
Belite Bio today announced that LBS-008, an orally administered tablet, has been granted fast track designation by the U.S. FDA for the treatment of Stargardt disease.
